Isavuconazole noninferior for invasive mold disease in hematologic malignancies
WASHINGTON, D.C. — In a subset of patients with hematologic malignancies, isavuconazole was noninferior to voriconazole in treating invasive mold disease, researchers reported here at ICAAC 2014.
Healio - Mon, 15 Sep 2014 14:33

Syros Pharmaceuticals Presents Research on Gene Control in Acute Myeloid ...
Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, announced today presentation of research at the American Association of Cancer Research (AACR) Hematologic Malignancies Meeting that ...
Rock Hill Herald (press release) - Tue, 23 Sep 2014 05:22

Olivier Danos Joins Biogen Idec as Senior Vice President, Gene Therapy
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978 ...
MarketWatch - Tue, 23 Sep 2014 04:02

High-dose melphalan plus ASCT significantly extended survival in newly ...
Antonio Palumbo, MD, of the department of hematology at University of Turin in Turin, Italy, and colleagues evaluated data from 273 patients aged 65 years or younger with newly diagnosed multiple myeloma. All patients underwent induction therapy, which ...
Healio - Tue, 23 Sep 2014 01:03

Biogen Idec Named Global Biotechnology Industry Leader on Dow Jones ...
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978 ...
MarketWatch - Tue, 23 Sep 2014 05:03

TG Therapeutics Announces Exercise of License Option for Its Novel, Next ...
... clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for cancer and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies.
CNNMoney - Tue, 23 Sep 2014 04:26

Lenalidomide–dexamethasone extended PFS, OS in transplant-ineligible ...
Researchers assigned 535 patients continuous lenalidomide–dexamethasone until disease progression; 541 patients to 18 cycles of the same combination; and 547 patients to melphalan (Alkeran, GlaxoSmithKline), prednisone and thalidomide (Thalomid ...
Healio - Mon, 22 Sep 2014 05:33

Progenics Pharmaceuticals Presents Long Term Follow-Up of Pivotal Phase 2 ...
The most common adverse events observed have been gastroenterological and hematologic disorders. As previously announced, Progenics has established an agreement with Canada'sCentre for Probe Development and Commercialization (CPDC) to ...
NASDAQ - Mon, 22 Sep 2014 05:44

Equities in Focus: RadioShack Corporation (NYSE:RSH), Progenics ...
Equities Focus (registration) - Mon, 22 Sep 2014 07:47


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014